Technology ID

Hydrocarbon Stapled Peptides that Inhibit the Linear Ubiquitin Chain Assembly Complex (LUBAC) for the Therapy of the Activated B Cell-like (ABC) Subtype of Diffuse Large B Bell Lymphoma (A Type of Non-Hodgkin’s Lymphoma)

Lead Inventor
Staudt, Louis (NCI)
Yang, Yiban (NCI)
Bernal, Federico (NCI)
Therapeutic Areas
Development Stages
Lead IC

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin’s lymphoma and consists of three subtypes: activated B-cell (ABC), germinal center B-cell (GBC), and primary mediastinal B-cell (PMB). Despite advances in the front-line therapy for DLBCL, approximately one-third of patients will relapse. Substantially worse outcomes have been reported for patients diagnosed with ABC DLBCL and treated with standard chemoimmunotherapy, suggesting the need for novel strategies that improve treatment outcomes.

ABC DLBCL cell survival depends largely upon NF-κB signaling being constitutively active. The linear ubiquitin chain assembly complex (LUBAC) participates in NF-κB signaling, consists of three proteins (HOIP, HOIL-1L, and SHARPIN), and protects against apoptosis. Inhibiting LUBAC using HOIP and/or SHARPIN peptide inhibitors attenuates LUBAC activity and promotes ABC DLBCL cell death.

LUBAC peptide inhibitors present a new therapeutic strategy for the treatment of ABC DLBCL and could be combined with radiation, chemotherapy, or CAR-T therapy for ABC DLBCL or other cancers. Researchers at the National Cancer Institute (NCI) have developed HOIP and SHARPIN peptides that inhibit HOIP/HOIL-IL (E-035-2013) and SHARPIN/HOIL-IL (E-019-2017) interactions, respectively. Additionally, these peptides could be applied to treat rheumatoid arthritis, chronic autoinflammation, systemic lupus erythematosus, Crohn's inflammatory bowel disease, polyglucosan body myopathy, or psoriasis. The NCI is seeking statements of capability or interest from parties interested in licensing or in collaborative research to co-develop technologies that disrupt NF-B signaling and present new therapeutic strategies for ABC DLBCL and inflammatory disease treatment. 

Competitive Advantages:

  • Novel composition of inhibitors for advanced stage ABC DLBCL
  • Effective therapies targeting the NF-κB pathway
  • Novel therapeutic for ABC DLBCL not responsive to R-CHOP or EPOCH therapies
  • In HeLa cells, SHARPIN-LTM peptides (E-019-2017) reduce Human Papilloma Virus-E6 and E7 expression at a dose of 10 µM, 5 times lower as curcumin, does to have the same effect;, and also, in half theof time thatof standard treatment needsed to reach a 50% decrease in viability (24h for LTM compared to 48 h for curcumin) (Molecules. 2015; 20:11830-60). Importantly thise SHARPIN peptide (E-019-2017) synergizes with Nutlin (currently in clinical trials) to reactivate p53 and decrease viability on HeLa cells at a 1:1 molar ratio (20 μM final concentration), which is lower than the 80 µM Nutlin dose needed to reach a similar effect.

Commercial Applications:

  • Targeted therapies of ABC DLBCL
  • Combination cytotoxic chemotherapies for ABC DLBCL treatment
  • Treatment of inflammatory diseases, such as polyglucosan body myopathy, rheumatoid arthritis, chronic autoinflammation, systemic lupus erythematosus, Crohn's inflammatory bowel disease, and psoriasis
Licensing Contact:
Nguyen-Antczak, Lauren